Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Nectar Lifesciences's Days Payable or its related term are showing as below:
NSE:NECLIFE'
s Days Payable Range Over the Past 10 Years
Min: 78.76 Med: 96.48 Max: 301.17
Current: 301.17
During the past 13 years, Nectar Lifesciences's highest Days Payable was 301.17. The lowest was 78.76. And the median was 96.48.
NSE:NECLIFE's Days Payable is ranked better than 90.51% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NSE:NECLIFE: 301.17
Nectar Lifesciences's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Nectar Lifesciences Days Payable Related Terms
Nectar Lifesciences Days Payable Historical Data
* Premium members only.
The historical data trend for Nectar Lifesciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nectar Lifesciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Nectar Lifesciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Nectar Lifesciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nectar Lifesciences (NSE:NECLIFE) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nectar Lifesciences and its competitors. Over the past decade, Nectar Lifesciences' Days Payable has ranged from 78.76 to 301.17. According to the industry distribution chart, Nectar Lifesciences ranks #88 out of 927 companies in the Drug Manufacturers industry, placing it in the top 9.5%.
Is Nectar Lifesciences' Days Payable too high?
Nectar Lifesciences' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 78.76 to a high of 301.17. Based on the distribution chart, Nectar Lifesciences ranks #88 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Nectar Lifesciences has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nectar Lifesciences ranks #88 out of 927 companies for Days Payable. This places Nectar Lifesciences in the top 10% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Historically, Nectar Lifesciences' own Days Payable has ranged from 78.76 to 301.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nectar Lifesciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nectar Lifesciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.78, compared to a current price of ₹10.90 — trading 60.8% above its estimated fair value. The current Days Payable is 0.00. Nectar Lifesciences' overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued.
The current stock price of ₹10.90 is trading 60.8% above its estimated GF Value™ of ₹6.78.
GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.
Key valuation signals for NSE:NECLIFE:
Days Payable: 0.00
GF Value™: ₹6.78 vs. price of ₹10.90 (60.8% above fair value)
No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
52GF Score
Get the complete analysis for NSE:NECLIFE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NECLIFE has been successfully added to your 
